These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15683597)

  • 1. Statin use in the metabolic syndrome.
    Lundbye JB; Thompson PD
    Curr Atheroscler Rep; 2005 Feb; 7(1):17-21. PubMed ID: 15683597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolic basis of atherogenic dyslipidemia.
    Vinik AI
    Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of the metabolic syndrome.
    Daskalopoulou SS; Mikhailidis DP; Elisaf M
    Angiology; 2004; 55(6):589-612. PubMed ID: 15547646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise Training Adaptations in Metabolic Syndrome Individuals on Chronic Statin Treatment.
    Morales-Palomo F; Ramirez-Jimenez M; Ortega JF; Moreno-Cabañas A; Mora-Rodriguez R
    J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31875915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
    Robins SJ
    Curr Opin Lipidol; 2003 Dec; 14(6):575-83. PubMed ID: 14624134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?
    Clearfield M; Pearce M; Nibbe Y; Crotty D; Wagner A
    Curr Atheroscler Rep; 2014 Jan; 16(1):380. PubMed ID: 24338517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome.
    Gogia A; Agarwal PK
    Indian J Med Sci; 2006 Feb; 60(2):72-81. PubMed ID: 16505579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
    Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
    Ginsberg HN; Stalenhoef AF
    J Cardiovasc Risk; 2003 Apr; 10(2):121-8. PubMed ID: 12668909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiometabolic syndrome: pathophysiology and treatment.
    Castro JP; El-Atat FA; McFarlane SI; Aneja A; Sowers JR
    Curr Hypertens Rep; 2003 Oct; 5(5):393-401. PubMed ID: 12948432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.